To the Editor After reading the Review by Tarantino et al1 recently published in JAMA Oncology, we became very excited to hopefully see a change in the paradigms for ERBB2-positive metastatic breast cancer (MBC) but also intrigued by some provocative suggestions.
First, to help clinicians define a population and hopefully allow inclusion in future-proof clinical trials, from the authors’ perspective, what is considered to be a long-term response? Is there a cutoff for this? Does it depend on the clinical trial inclusion criteria met by the patient?
Rala de Paula BH, Crocamo S. Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”? JAMA Oncol. 2022;8(8):1220–1221. doi:10.1001/jamaoncol.2022.1919
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.